ZBHHealthcare · Medical DevicesThe 28 Wall Street analysts covering Zimmer Biomet Holdings, Inc. hold a median 12-month price target of $105 — +14.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Zimmer Biomet Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (50): The shares have been drifting down relative to others.
Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ZBH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.4% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | $100 |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Hold | $83 → $100 |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 7 Aug 2026 | Truist Securities | Maintains | Hold | — |
| 7 Aug 2026 | Truist Securities | Maintains | Hold | $92 → $106 |
| 6 Aug 2026 | Bernstein | Maintains | Market Perform | — |
| 6 Aug 2026 | Bernstein | Maintains | Market Perform | $91 → $93 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $101 → $110 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Aug 2026 | Stifel | Maintains | Buy | — |
| 6 Aug 2026 | Stifel | Maintains | Buy | $105 → $110 |
| 28 July 2026 | UBS | Assumes | Buy | $89 → $115 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | $95 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $120 → $110 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 29 Apr 2026 | Barclays | Maintains | Underweight | — |
| 29 Apr 2026 | Citigroup | Maintains | Neutral | — |
| 29 Apr 2026 | Citizens | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZBH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Zimmer Biomet Holdings, Inc. returned −5.7% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 33% of US stocks
Cheaper than 51% of US stocks
Cheaper than 56% of US stocks
Cheaper than 38% of US stocks
Higher than 38% of US stocks
Higher than 65% of US stocks
Higher than 83% of US stocks
Higher than 76% of US stocks
Higher than 69% of US stocks
Higher than 56% of US stocks
Higher than 70% of US stocks
Higher than 71% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zimmer Biomet Holdings, Inc. has a market value of $17.6B and an enterprise value of $24.7B.
Revenue in the twelve months to 30 June 2026: $8.5B. The latest quarter grew 4.8% year on year.
Net income over the same four quarters: $807.0M, a 9.5% net margin.
Free cash flow in the twelve months to 30 June 2026: $1.4B.
Zimmer Biomet Holdings, Inc. spent $750.8M on share buybacks and $188.4M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 22.3×; forward P/E: 10.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.04%, paying out 23% of earnings.
Zimmer Biomet Holdings, Inc. employs 17,000 people — $501K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zimmer Biomet Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zimmer Biomet and Think Surgical extended their exclusive distribution agreement for multiple years. The extension is intended to help accelerate adoption of the wireless, handheld TMINI system for use with Zimmer Biomet's Persona knee system.
Why it matters — The agreement supports distribution of a surgical system designed for use with Zimmer Biomet's Persona knee system.
Zacks Investment Research says its stock analysis focuses on the Zacks Rank system, which uses earnings estimates and estimate revisions, while also tracking value, growth, and momentum trends. The excerpt does not provide a specific assessment of Zimmer Biomet.
Why it matters — ZBH watchers get context on the factors Zacks considers, but the excerpt does not state whether ZBH meets those criteria.
Zacks Investment Research highlights its Style Scores feature, which it says helps investors find stocks across value, growth, and momentum styles. The headline identifies Zimmer Biomet (ZBH) as a top-ranked value stock.
Why it matters — The item presents ZBH in a value-investing context and points readers to Zacks’ stock-ranking feature.
Zimmer Biomet announced that it will webcast its third-quarter 2026 earnings conference call on Wednesday, November 4, 2026, at 8:30 a.m.
Why it matters — The call will provide ZBH watchers with an opportunity to hear the company’s third-quarter financial results.
Zacks Investment Research published an article explaining why Zimmer Biomet (ZBH) is considered a strong value stock, highlighting the Zacks Style Scores feature of its Zacks Premium research service as a tool that helps investors identify strong stocks.
Why it matters — A ZBH watcher would care because this report indicates analysts view Zimmer Biomet favorably on valuation metrics within the Zacks research framework.
The 28 Wall Street analysts covering Zimmer Biomet Holdings, Inc. have a median 12-month price target of $105, with estimates ranging from $93 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Zimmer Biomet Holdings, Inc., 9 rate it a Buy, 19 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zimmer Biomet Holdings, Inc. 91 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Zimmer Biomet Holdings, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +14.4% from the last close, and Ticker Nerd's factor model ranks Zimmer Biomet Holdings, Inc. 91 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zimmer Biomet Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $93 to $130 over the next 12 months.
Zimmer Biomet Holdings, Inc. returned -5.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Zimmer Biomet Holdings Inc. is a global medical technology company focused on musculoskeletal healthcare.
The most recent item we track (PRNewsWire, 13 Oct 2026): "ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT". Zimmer Biomet and Think Surgical extended their exclusive distribution agreement for multiple years. The extension is intended to help accelerate adoption of the wireless, handheld TMINI system for use with Zimmer Biomet's Persona knee system.
Zimmer Biomet Holdings Inc. is a global medical technology company focused on musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip systems, along with sports medicine, biologics, extremities, and trauma solutions. Its portfolio also includes craniomaxillofacial and thoracic products, office-based technologies, bone cement, surgical instruments, and integrated digital and robotic technologies used in orthopedic procedures. Zimmer Biomet serves healthcare professionals, hospitals, and surgical centers by providing products that support the treatment of bone, joint, and soft-tissue disorders. Headquartered in Warsaw, Indiana, Zimmer Biomet plays an important role in orthopedic care across major markets worldwide.
CEO Mr. Ivan Tornos · 17,000 employees · United States · https://www.zimmerbiomet.com
